Skip to main content
SpringerLink
Log in

Restarting Clozapine after Neutropenia

Evaluating the Possibilities and Practicalities

  • Therapy in Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Clozapine remains the antipsychotic of choice for refractory schizophrenia despite its propensity for serious blood disorders. When neutropenia or agranulocytosis occur in people taking clozapine, cessation of treatment is mandated and relapse often results. Because such patients are usually unresponsive to other antipsychotics, many clinicians consider restarting clozapine, despite the risks involved. However, the risks of clozapine rechallenge vary according to the cause and nature of the blood dyscrasia.

Neutropenia can arise because of factors unrelated or indirectly related to clozapine treatment. These include benign ethnic neutropenia, concomitant drug therapy, co-existing medical conditions and drug interactions. In such cases, clozapine may be restarted if non-clozapine causes of neutropenia are identified and eliminated, although concurrent treatment with lithium (to induce leukocytosis) is sometimes necessary. Close monitoring of the patient is essential because it is rarely possible to completely rule out the contribution of clozapine to the blood dyscrasia and because lithium does not protect against clozapine-related agranulocytosis. In cases of clozapine-induced neutropenia (as distinct from agranulocytosis, which may have a different pathology) rechallenge may also be considered and, again, lithium co-therapy may be required.

Where clozapine is clearly the cause of agranulocytosis, rechallenge should not be considered or undertaken unless there are very exceptional circumstances (severe and prolonged relapse following clozapine discontinuation). In these cases, re-exposure to clozapine may rarely be attempted where there are facilities for very close and frequent monitoring. Granulocyte colony-stimulating factor is likely to be required as co-therapy, given the very high likelihood of recurrence.

Uncertainty over the likely cause of blood dyscrasia in people taking clozapine, coupled with uncertainty over the mechanism by which clozapine causes both neutropenia and agranulocytosis, makes any attempt to restart clozapine a high-risk venture requiring the utmost caution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64

    CAS  PubMed  Google Scholar 

  2. Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000; 14: 409–18

    CAS  PubMed  Google Scholar 

  3. Gaebel W, Weinmann S, Sartorius N, et al. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187: 248–55

    PubMed  Google Scholar 

  4. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30–4

    PubMed  Google Scholar 

  5. Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. J Clin Psychiatry 1999; 60: 47–50

    CAS  PubMed  Google Scholar 

  6. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82–91

    CAS  Google Scholar 

  7. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    CAS  PubMed  Google Scholar 

  8. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–6

    CAS  PubMed  Google Scholar 

  9. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000; 61: 14–7

    CAS  PubMed  Google Scholar 

  10. Alvir JMJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55: 137–8

    PubMed  Google Scholar 

  11. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483–8

    CAS  PubMed  Google Scholar 

  12. Munro J, O’Sullivan D, Andrews C, et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 1999; 175: 576–80

    CAS  PubMed  Google Scholar 

  13. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155–6

    CAS  PubMed  Google Scholar 

  14. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–5

    Google Scholar 

  15. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81

    CAS  PubMed  Google Scholar 

  16. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416–32

    CAS  PubMed  Google Scholar 

  17. Naber D. Optimising clozapine treatment. J Clin Psychiatry 1999; 60: 35–8

    PubMed  Google Scholar 

  18. Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv 2000; 51: 666–8

    CAS  PubMed  Google Scholar 

  19. Taylor D, Shapland L, Laverick G, et al. Clozapine: a survey of patient perceptions. Psychiatr Bull 2000; 24: 450–2

    Google Scholar 

  20. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61: 382–6

    CAS  PubMed  Google Scholar 

  21. Ciapparelli A, Dell’Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64: 451–8

    CAS  PubMed  Google Scholar 

  22. Lieberman JA, McEvoy JP, Swartz MS, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23

    CAS  PubMed  Google Scholar 

  23. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10

    PubMed  Google Scholar 

  24. Pirmohamed M, Park K. Mechanism of clozapine-induced agranulocytosis. CNS Drugs 1997; 7: 139–58

    CAS  PubMed  Google Scholar 

  25. Gerson SL. Clozapine: deciphering the risks. N Engl J Med 1993; 329: 204–5

    CAS  PubMed  Google Scholar 

  26. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58: 207–16

    CAS  PubMed  Google Scholar 

  27. Safferman AZ, Lieberman JA, Alvir JMJ, et al. Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339: 1296–7

    CAS  PubMed  Google Scholar 

  28. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255–63

    PubMed  Google Scholar 

  29. Pisciotta AV, Konings SA, Ciesemier LL, et al. On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Saf 1992; 7: 33–44

    PubMed  Google Scholar 

  30. Gerson SL, Meltzer HY. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7: 17–25

    PubMed  Google Scholar 

  31. Fischer V, Haar JA, Greiner L, et al. Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol Pharmacol 1991; 40: 846–53

    CAS  PubMed  Google Scholar 

  32. Uetrecht JP. Metabolism of clozapine by neutrophils. Drug Saf 1992; 7: 51–6

    CAS  PubMed  Google Scholar 

  33. Williams DP, Pirmohamed M, Naisbitt DJ, et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 1997; 283: 1375–82

    CAS  PubMed  Google Scholar 

  34. Tschen AC, Rieder MJ, Oyewumi KL, et al. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 1999; 65: 526–32

    CAS  PubMed  Google Scholar 

  35. Loeffler S, Fehsel K, Henning U, et al. Increased apoptosis of neutrophils in a case of clozapine-induced agranulocytosis. Pharmacopsychiatry 2003; 36: 37–41

    CAS  PubMed  Google Scholar 

  36. Hummer M, Kurz M, Barnas C, et al. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 1994; 55: 429–32

    CAS  PubMed  Google Scholar 

  37. Beer D, Cope S, Paton C, et al. Clozapine-induced neutropenia — or not [letter]. Br J Psychiatry 1994; 164: 850A

    CAS  PubMed  Google Scholar 

  38. Esposito D, Aouille J, Rouillon F, et al. Morning pseudoneu-tropenia during clozapine treatment. World J Biol Psychiatry 2003; 4: 192–4

    PubMed  Google Scholar 

  39. Ahokas A, Elonen E. Circadian rhythm of white blood cells during clozapine treatment. Psychopharmacology 1999; 144: 301–2

    CAS  PubMed  Google Scholar 

  40. Murray P, Laurent A. Is it possible to distinguish between benign and malignant neutropenia in clozapine-treated patients by means of a hydrocortisone test? Psychopharmacology 2001; 158: 329–30

    Google Scholar 

  41. Jauss M, Pantel J, Werle E, et al. G-CSF plasma levels in clozapine-induced neutropenia. Biol Psychiatry 2000; 48: 1113–5

    CAS  PubMed  Google Scholar 

  42. Montera D, Santamaria B, Rayon P, et al. Time for less control of clozapine? Lancet 1995; 346: 56–7

    Google Scholar 

  43. Sedky K, Shaughnessy R, Hughes T, et al. Clozapine-induced agranulocytosis after 11 years of treatment [letter]. Am J Psychiatry 2005; 162: 814

    PubMed  Google Scholar 

  44. Patel NC, Dorson PG, Bettinger TL. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002; 36: 1012–5

    PubMed  Google Scholar 

  45. Feldman J. Clozapine and agranulocytosis. Psychiatr Serv 1996; 47: 1177–8

    CAS  PubMed  Google Scholar 

  46. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945–8

    CAS  PubMed  Google Scholar 

  47. Dealing M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001; 11: 135–41

    Google Scholar 

  48. Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998; 25: 11–3

    CAS  PubMed  Google Scholar 

  49. Pfister GM, Hanson DR, Roerig JL, et al. Clozapine-induced agranulocytosis in a native American: HLA typing and further support for an immune-mediated mechanism. J Clin Psychiatry 1992; 53: 242–4

    CAS  PubMed  Google Scholar 

  50. Claas FH, Abbott PA, Witvliet MD, et al. No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis. Drug Saf 1992; 7: 3–6

    PubMed  Google Scholar 

  51. Imbarlina MJ, Sarkar S, Marwah S, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatry 2004; 19: 506–9

    PubMed  Google Scholar 

  52. Pantelis C, Adesanya A. Increased risk of neutropenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatry 2001; 35: 544–5

    CAS  PubMed  Google Scholar 

  53. Kando JC, Tohen M, Castillo J, et al. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55: 255–7

    CAS  PubMed  Google Scholar 

  54. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996; 153: 735–6

    CAS  PubMed  Google Scholar 

  55. Diaz P, Hogan T. Granulocytopenia with clozapine and quetiapine[letter]. Am J Psychiatry 2001; 158: 651

    CAS  PubMed  Google Scholar 

  56. Schafer M, Schmidt F, Grunze H, et al. Interferon alpha-associated agranulocytosis during clozapine treatment: case report and status of current knowledge [in German]. Nervenarzt 2001; 72: 872–5

    CAS  PubMed  Google Scholar 

  57. Usiskin SI, Nicolson R, Lenane M, et al. Retreatment with clozapine after erythromycin-induced neutropenia [letter]. Am J Psychiatry 2000; 157: 1021

    CAS  PubMed  Google Scholar 

  58. Senechal A, Landry P, Deschamps R, et al. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002; 28: 567–79

    CAS  PubMed  Google Scholar 

  59. Avnon M, Stolerman I. Clozapine, cancer, and schizophrenia. Am J Psychiatry 1993; 150: 1562–3

    CAS  PubMed  Google Scholar 

  60. Wesson ML, Finnegan DM, Clark PI. Continuing clozapine despite neutropenia. Br J Psychiatry 1996; 168: 217–20

    CAS  PubMed  Google Scholar 

  61. Rosenstock J. Clozapine therapy during cancer treatment [letter]. Am J Psychiatry 2004; 161: 175

    PubMed  Google Scholar 

  62. Dettling M, Mueller-Oerlinghausen B, Britsch P. Clozapine treatment of HIV-associated psychosis: too much bone marrow toxicity? Pharmacopsychiatry 1998; 31: 156–7

    CAS  PubMed  Google Scholar 

  63. Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999; 14: 128–31

    CAS  PubMed  Google Scholar 

  64. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999; 133:15–22

    CAS  PubMed  Google Scholar 

  65. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 2005; 81: 545–6

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Papadaki HA, Eliopoulos GD. An overview on the diagnosis, classification and differential diagnosis of chronic neutropenias. Haema 2002; 5: 39–49

    Google Scholar 

  67. Stein RS, Hanson G, Koethe S, et al. Lithium-induced granulocytosis. Ann Intern Med 1978; 88: 809–10

    CAS  PubMed  Google Scholar 

  68. Lapierre G, Stewart RB. Lithium carbonate and leukocytosis. Am J Hosp Pharm 1980; 37: 1525–8

    CAS  PubMed  Google Scholar 

  69. Pi EH, Sramek JJ, Simpson GM. Effect of lithium on leukocytes: a two-year follow-up. J Clin Psychiatry 1983; 44: 139–40

    CAS  PubMed  Google Scholar 

  70. Rothstein G, Clarkson DR, Larsen W, et al. Effect of lithium on neutrophil mass and production. N Engl J Med 1978; 26: 178–80

    Google Scholar 

  71. Ozdemir MA, Sofuoglu S, Tanrikulu G, et al. Lithium-induced hematologic changes in patients with bipolar affective disorder. Biol Psychiatry 1994; 35: 210–3

    CAS  PubMed  Google Scholar 

  72. Small JG, Klapper MH, Malloy FW, et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003; 23: 223–8

    CAS  PubMed  Google Scholar 

  73. Catane R, Kaufman J, Mittelman A, et al. Attenuation of myelosuppression with lithium. N Engl J Med 1977; 297: 452–3

    CAS  PubMed  Google Scholar 

  74. Richman CM, Makii MM, Weiser PA. The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. Am J Hematol 1984; 16: 313–23

    CAS  PubMed  Google Scholar 

  75. Gupta RC, Robinson WA, Smyth CJ. Efficacy of lithium in rheumatoid arthritis with granulocytopenia. Arthritis Rheum 1975; 18: 179–84

    CAS  PubMed  Google Scholar 

  76. Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. Am J Psychiatry 1990; 147: 615–20

    CAS  PubMed  Google Scholar 

  77. Roberts DE, Berman SM, Nakasato S, et al. Effect of lithium carbonate on zidovudine-associated neutropenia in the acquired immunodeficiency syndrome. Am J Med 1988; 85: 428–31

    CAS  PubMed  Google Scholar 

  78. Adityanjee A. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry 1995; 152: 648–9

    CAS  PubMed  Google Scholar 

  79. Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol 1998; 18: 86–8

    CAS  PubMed  Google Scholar 

  80. Blier P, Slater S, Measham T, et al. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 1998; 13: 137–40

    CAS  PubMed  Google Scholar 

  81. Boshes RA, Manschreck TC, Desrosiers J, et al. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry 2001; 13: 233–7

    CAS  PubMed  Google Scholar 

  82. Valevski A, Modai I, Lahav M, et al. Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 1993; 8: 63–5

    CAS  PubMed  Google Scholar 

  83. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003; 13: 401–4

    PubMed  Google Scholar 

  84. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006; 67: 756–60

    CAS  PubMed  Google Scholar 

  85. Gerson SL, Lieberman JA, Friedenberg WR, et al. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 1991; 338: 262–3

    CAS  PubMed  Google Scholar 

  86. Blake LM, Marks RC, Luchins DJ. Reversible neurologic symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12: 297–9

    CAS  PubMed  Google Scholar 

  87. Garcia G, Crismon ML, Dorson PG. Scizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994; 14: 426–8

    CAS  PubMed  Google Scholar 

  88. Bell AJ, Cole A, Eccleston D, et al. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993; 162: 689–92

    CAS  PubMed  Google Scholar 

  89. Bender S, Linka T, Wolstein J, et al. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol 2004; 7: 59–63

    CAS  PubMed  Google Scholar 

  90. Gerson SL, Gullion G, Yeh HS, et al. Granulocyte colonystimulating factor for clozapine-induced agranulocytosis. Lancet 1992; 340: 1097

    CAS  PubMed  Google Scholar 

  91. Lamberti JS, Bellnier TJ, Schwarzkopf SB, et al. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995; 56: 256–9

    CAS  PubMed  Google Scholar 

  92. Sperner-Unterweger B, Czeipek I, Gaggl S, et al. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Br J Psychiatry 1998; 172: 82–4

    CAS  PubMed  Google Scholar 

  93. Chin-Yee I, Bezchlibnyk-Butler K, Wong L. Use of cytokines in clozapine-induced agranulocytosis. Can J Psychiatry 1996; 41: 280–4

    CAS  PubMed  Google Scholar 

  94. Conus P, Nanzer N, Baumann P. An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. Br J Psychiatry 2001; 179: 180

    CAS  PubMed  Google Scholar 

  95. Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 2003; 18: 173–4

    PubMed  Google Scholar 

Download references

Acknowledgements

Eromona Whiskey has no conflicts of interest that are directly relevant to the content of this review. David Taylor has received grants from Bristol-Myers Squibb and Novartis, honoraria from Bristol-Myers Squibb, Novartis and Genthon, and acted as a consultant for Bristol-Myers Squibb, Sanofi-Synthelabo and AstraZeneca. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Pharmacy Department, Maudsley Hospital, South London and Maudsley NHS Trust, Denmark Hill, London, SE5 8AZ, UK

    Eromona Whiskey &  David Taylor

Authors
  1. Eromona Whiskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Taylor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whiskey, E., Taylor, D. Restarting Clozapine after Neutropenia. CNS Drugs 21, 25–35 (2007). https://doi.org/10.2165/00023210-200721010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721010-00003

Keywords

Search

Navigation